ERBB2 and breast carcinoma: Thus, to assess the clinical utility of nab-paclitaxel in NAC, we conducted this retrospective study to compare the efficacy and toxicity of nab-paclitaxel-based with those of docetaxel-based regimens used in patients with HER2-negative breast cancer.